Tumor cell checkpoints

iOmx is discovering checkpoints that may work where PD-1/L1 doesn’t

iOmx Therapeutics AG is taking a systematic approach to identifying targets located on tumors that modify T cell activation. The resulting targets are complementary to but independent of PD-1/PD-L1 signaling, which may provide a way to treat patients who don’t respond to PD-1/PD-L1 inhibitors.

The company is starting with more than 20 checkpoint targets on tumor cells, the majority of which previously had no known function in cancer or immunology,

Read the full 703 word article

User Sign In